C3a Pretreatment Enhances CXCR4-Mediated Stem Cell Homing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge in bone marrow transplantation is the delayed engraftment and low efficiency of umbilical cord blood-derived CD34+ hematopoietic stem cells due to their lower cellular content and sensitivity to SDF-1 gradients, which affects the homing and engraftment of these cells in the bone marrow.
Innovation Solution
Pretreating umbilical cord blood cells with agents such as C3 complement cleavage fragments (C3a and desArgC3a), fibronectin, fibrinogen, and hyaluronic acid to enhance the responsiveness of CD34+ stem cells to SDF-1 signaling, thereby improving their homing and engraftment by activating the CXCR-4 receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If umbilical cord blood stem cells are used for bone marrow transplantation, then the procedure is non-controversial and offers off-the-shelf therapeutic products, but the cellular content is a log order less than bone marrow or mobilized peripheral cells, resulting in delayed engraftment
Solution Approach 1:
The patent applies preliminary action by pretreating umbilical cord blood stem cells with agents that activate CXCR-4 receptors before transplantation. This pre-activation enhances the cells' responsiveness to SDF-1 gradients, improving homing and engraftment efficiency without changing the source material or processing steps after collection.
Solution Approach 2:
The patent changes the functional parameters of the stem cells by modulating CXCR-4 receptor activity through pretreatment with activating agents. This alters the cells' sensitivity to chemokine gradients, enabling more efficient homing and engraftment despite the lower cellular content in umbilical cord blood compared to adult donors.
2Reliability
If umbilical cord blood stem cells are infused, then they can engraft in bone marrow, but the engraftment is delayed and the cells are sensitive to SDF-1 gradients, affecting homing efficiency
Solution Approach 1:
The patent applies preliminary action by pretreating umbilical cord blood stem cells with agents that activate CXCR-4 receptors before transplantation. This pre-activation enhances the cells' responsiveness to SDF-1 gradients, improving homing and engraftment efficiency without changing the source material or processing steps after collection.
Solution Approach 2:
The patent uses SDF-1 (stromal cell-derived factor-1) as an intermediary chemokine that mediates the homing of stem cells to the bone marrow. By activating CXCR-4 receptors on the stem cells, the treatment enhances their sensitivity to SDF-1 gradients, facilitating more efficient and timely homing to the bone marrow microenvironment.
3Reliability
If activation of the complement system occurs during stress response, then it is part of the normal immune response, but proteases in the marrow reduce SDF-1 concentration, lessening homing and engraftment
Solution Approach 1:
The patent applies preliminary action by pretreating umbilical cord blood stem cells with agents that activate CXCR-4 receptors before transplantation. This pre-activation enhances the cells' responsiveness to SDF-1 gradients, improving homing and engraftment efficiency without changing the source material or processing steps after collection.
Solution Approach 2:
The patent converts the potentially harmful effect of complement activation and protease activity into a benefit by using these same mechanisms to prime CXCR-4 receptors on stem cells. The pretreatment with complement fragments or other activating agents enhances receptor sensitivity, allowing the cells to overcome the diluting effect of proteases in the marrow and maintain effective homing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach increases the efficiency of engraftment of umbilical cord blood stem cells, reducing the time to hematopoietic recovery and minimizing the risk of transplant-related mortality by enhancing the cells' sensitivity to SDF-1 gradients, thus improving the success rate of bone marrow transplantation.
Implementation Method 1
Pretreating umbilical cord blood cells with agents such as C3 complement cleavage fragments (C3a and desArgC3a)... to enhance the responsiveness of CD34+ stem cells to SDF-1 signaling
Implementation Method 2
Pretreating umbilical cord blood cells with agents such as C3 complement cleavage fragments (C3a and desArgC3a), fibronectin, fibrinogen, and hyaluronic acid to enhance the responsiveness of CD34+ stem cells to SDF-1 signaling, thereby improving their homing and engraftment by activating the CXCR-4 receptor
Implementation Method 3
Cells expressing CD34 (CD34+ cell) are normally found in the umbilical cord and bone marrow as hematopoietic cells and tend to migrate from the blood stream to the bone marrow along a gradient of stromal derived factor-1 (SDF-1) where SDF-1 levels are high in the bone marrow and low in the peripheral blood
Data Source
AI summary
The present invention provides for enhancing engraftment by co-infusing at least two partially HLA matched umbilical cord blood (“UCB”) units. The invention further provides for positive C3a mediated priming on responsiveness to doses of SDF-1 and C3a induced incorporation of CXCR4 in membranes in HSC and progenitors. The invention further provides for enhancing the homing of UCB HSC and progenitors via the SDF-1/CXCR4 pathway and that C3a and LL-37 are useful for this method. It is also disclosed herein that fragments of C3a (e.g., des-Arg) are effective in the methods of the invention, including enhancing homing of HSPCs to BM. The invention further encompasses the disclosure herein of NFAT1 regulation post-transcriptionally by both mir-184 and IFN-γ. The present invention further provides for measuring and using differences between UCB and adult CD4+/45RA+ T-cells as a means of defining strategies to enhance optimal allogeneic stem cell transplantation outcomes. The present invention further provides methods for maintaining IL-2 production in the absence of NFAT1 normal protein levels.